Icosapent - Lipid modification

You are here : Home > Formulary Search > Icosapent - Lipid modification

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green

Formulations :

Capsules

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Associated Icons :

Guidelines BNF SPC

NICE

Restrictions / Comments :

Important

With statin therapy in patients with raised triglycerides

Documentation

Evidence Review

Icosapent ethyl - NICE TA805 Briefing paper for APC - Oct 22

Webpage

NICE TA805 - Icosapent ethyl with statin therapy in people with raised triglycerides - Jul 22

PAD Profile

ChemicalSubstance :

Icosapent

Indication :

Lipid modification

Group Name :

Keywords :

raised triglycerides, hypertriglyceridaemia

Brand Names Include :

Vazkepa

Important Information :

Latest Additions Date From :

Latest Additions Date To :

Guidelines :

Lipid modification

Supporting Documents :

Other Indications

Below are listed other indications that Icosapent is used to treat.

No records returned.

Other Drugs

Below are listed other drugs that are used to treat Lipid modification.

Committee Recommendations (1)

05 Oct 22 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands integrated care system Area Prescribing Committee (APC) approve Icosapent ethyl with statin therapy as a treatment option for reducing the risk of cardiovascular events in people with raised triglycerides in line with NICE TA805.
Icosapent ethyl for this indication will be considered as GREEN on the traffic light status.
The committee noted an increased risk of atrial fibrillation or fluttter - prescribers should consider advice given in the Summary of Product Charcteristics available at https://www.medicines.org.uk/emc/product/12964